Hemab Therapeutics, a biotechnology research company in Copenhagen, Capital Region of Denmark, is pleased to announce it has raised over $135 million in its Series B round of financing. The new capital will be used to expand the company's pipeline of innovative therapies for cancer and rare genetic diseases.

In addition to the financial support from existing investors like Novo Holdings, RA Capital Management, and HealthCap, new investors such as Avoro Capital Advisors, Access Industries, The Invus Group, Rock Springs Capital, and Maj Invest Equity joined this round of financing.

This financing will back Hemab's corporate and scientific growth goals up until 2025, including the conclusion of an ongoing Phase 1/2 clinical trial for leading product HMB-001 in Glanzmann Thrombasthenia, initiating pivotal studies, starting and finishing a Phase 1/2 clinical assessment for HMB-VWF in von Willebrand disease, as well as future pipeline expansion following the company's Hemab 1-2-5™ strategic direction— aiming to have five clinical assets established by 2025.

Hemab is committed to advancing its cutting-edge genome engineering technologies into clinical trials with potentially life-saving treatments for cancer patients and rare genetic diseases. The founder of Hemab Therapeutics, Benny Sorensen, said, "We are grateful for the continued confidence our partners have placed in us as we work towards making a difference in people's lives."